ViiV Healthcare Gains Breakthrough Status for HIV PrEP

November 20, 2020

ViiV Healthcare’s investigational drug cabotegravir, an HIV pre-exposure prophylaxis (PrEP),  has received a Breakthrough Therapy designation from the FDA.

The long-lasting injectable drug earned the Breakthrough Therapy designation based on results from its phase 2b/3 trial that showed it was 66 percent more effective at preventing HIV compared to daily oral emtricitabine/tenofovir disoproxil fumarate.

The study involved 4,566 men who have sex with men and spanned research sites in the U.S., Argentina, Brazil, Peru, South Africa, Thailand and Vietnam.

View today's stories